📣 VC round data is live. Check it out!

Ebos Group Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ebos Group and similar public comparables like Fragua, Kusuri No Aoki, Sundrug, Omnicell and more.

Ebos Group Overview

About Ebos Group

Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government’s Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.


Founded

1922

HQ

Australia

Employees

5.8K

Sectors

Financials (LTM)

Revenue: $10B
EBITDA: $468M

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Ebos Group Financials

Ebos Group reported last 12-month revenue of $10B and EBITDA of $468M.

In the same LTM period, Ebos Group generated $1B in gross profit, $468M in EBITDA, and $179M in net income.

Revenue (LTM)


Ebos Group P&L

In the most recent fiscal year, Ebos Group reported revenue of $8B and EBITDA of $379M.

Ebos Group is profitable as of last fiscal year, with gross margin of 13%, EBITDA margin of 5%, and net margin of 2%.

See analyst estimates for Ebos Group
LTMLast FY202320242025202620272028
Revenue$10B$8B$8B$8B$9B
Gross Profit$1B$1B$1B$1B$1B
Gross Margin13%13%13%13%13%
EBITDA$468M$379M$374M$363M$411M
EBITDA Margin5%5%5%4%5%
EBIT Margin3%4%4%4%3%
Net Profit$179M$167M$169M$156M$158M
Net Margin2%2%2%2%2%
Net Debt$584M

Financial data powered by Morningstar, Inc.

Ebos Group Stock Performance

Ebos Group has current market cap of $3B, and enterprise value of $4B.

Market Cap Evolution


Ebos Group's stock price is $12.36.

Ebos Group share price decreased by 0.6% in the last 30 days, and by 43.1% in the last year.

Ebos Group has an EPS (earnings per share) of $0.82.

See more trading valuation data for Ebos Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$3B0.4%-0.6%-12.8%-43.1%$0.82

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Ebos Group Valuation Multiples

Ebos Group trades at 0.4x EV/Revenue multiple, and 7.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Ebos Group

EV / Revenue (LTM)


Ebos Group Financial Valuation Multiples

As of May 16, 2026, Ebos Group has market cap of $3B and EV of $4B.

Ebos Group has a P/E ratio of 14.2x.

LTMLast FY202320242025202620272028
EV/Revenue0.4x0.5x0.4x0.4x0.4x
EV/EBITDA7.7x9.6x9.7x10.0x8.8x
EV/EBIT11.0x12.2x12.0x12.5x12.0x
EV/Gross Profit2.9x3.5x3.5x3.5x3.1x
P/E14.2x15.1x15.0x16.2x16.0x
EV/FCF39.0x15.5x20.2x17.9x22.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Ebos Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Ebos Group Margins & Growth Rates

Ebos Group grew revenue by 22% and EBITDA by 27% in the last fiscal year.

In the most recent fiscal year, Ebos Group reported gross margin of 13%, EBITDA margin of 5%, and net margin of 2%.

See estimated margins and future growth rates for Ebos Group

Ebos Group Margins

Last FY202420252026202720282029
Gross Margin13%13%13%14%
EBITDA Margin5%4%5%5%
EBIT Margin4%4%3%3%
Net Margin2%2%2%2%
FCF Margin3%2%2%2%

Ebos Group Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth22%(0%)7%13%
Gross Profit Growth27%2%13%14%
EBITDA Growth27%(3%)13%16%
EBIT Growth13%(4%)4%14%
Net Profit Growth8%(8%)2%17%
FCF Growth(63%)13%(21%)(5%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Ebos Group Operational KPIs

Ebos Group's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $0.1M for the same period.

Ebos Group's Rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ebos Group's Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Ebos Group
LTMLast FY202320242025202620272028
Rule of 4011%18%
Bessemer Rule of X20%38%
Revenue per Employee$1.4M
Opex per Employee$0.1M
G&A Expenses to Revenue5%4%5%4%
Opex to Revenue10%9%9%9%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Ebos Group Competitors

Ebos Group competitors include Fragua, Kusuri No Aoki, Sundrug, Omnicell, COSMOS Pharmaceutical, Dis-Chem Pharmacies, DaShenLin Pharmaceutical, Nahdi Medical, Clicks Group and Sugi Holdings.

Most Ebos Group public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Fragua0.4x0.3x6.9x4.3x
Kusuri No Aoki0.8x0.8x10.6x11.1x
Sundrug0.5x0.5x6.9x6.3x
Omnicell1.6x1.6x13.7x12.9x
COSMOS Pharmaceutical0.5x0.5x7.7x7.8x
Dis-Chem Pharmacies0.9x0.8x11.1x10.6x
DaShenLin Pharmaceutical0.7x0.7x5.6x5.7x
Nahdi Medical1.3x1.3x7.7x7.7x

This data is available for Pro users. Sign up to see all Ebos Group competitors and their valuation data.

Start Free Trial

Ebos Group M&A Activity

Ebos Group has acquired 3 companies to date.

Last acquisition by Ebos Group was on July 31st 2023. Ebos Group acquired Superior Pet Food Co. for $50M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Ebos Group

Superior Pet Food Co.
LifeHealthcare
HPS Services
Description
LifeHealthcare is an Australian distributor of specialized medical devices across surgical, biologics, and capital equipment divisions. Partnering with global innovators, it supplies orthopedic implants, endoscopy tools, wound care products, and infusion pumps to hospitals and clinics nationwide from its Melbourne headquarters.
HPS Services is a Melbourne-based supplier of pharmaceutical services to Australian healthcare facilities. It wholesales medications, delivers to private hospitals, public wards, cancer centers, and correctional centers through a network of 20 pharmacies. Operating since 1995, HPS provides 24/7 emergency supply and cold chain logistics nationwide.
HQ CountryNew ZealandAustraliaAustralia
HQ City
Sydney
Ashford
Deal Date31 Jul 20239 Dec 202123 May 2017
Valuation$50M$834M$100M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Ebos Group acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Ebos Group

When was Ebos Group founded?Ebos Group was founded in 1922.
Where is Ebos Group headquartered?Ebos Group is headquartered in Australia.
How many employees does Ebos Group have?As of today, Ebos Group has over 5K employees.
Is Ebos Group publicly listed?Yes, Ebos Group is a public company listed on New Zealand Exchange.
What is the stock symbol of Ebos Group?Ebos Group trades under EBO ticker.
When did Ebos Group go public?Ebos Group went public in 1960.
Who are competitors of Ebos Group?Ebos Group main competitors include Fragua, Kusuri No Aoki, Sundrug, Omnicell, COSMOS Pharmaceutical, Dis-Chem Pharmacies, DaShenLin Pharmaceutical, Nahdi Medical, Clicks Group, Sugi Holdings.
What is the current market cap of Ebos Group?Ebos Group's current market cap is $3B.
What is the current revenue of Ebos Group?Ebos Group's last 12 months revenue is $10B.
What is the current revenue growth of Ebos Group?Ebos Group revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Ebos Group?Current revenue multiple of Ebos Group is 0.4x.
Is Ebos Group profitable?Yes, Ebos Group is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Ebos Group?Ebos Group's last 12 months EBITDA is $468M.
What is Ebos Group's EBITDA margin?Ebos Group's last 12 months EBITDA margin is 5%.
What is the current EV/EBITDA multiple of Ebos Group?Current EBITDA multiple of Ebos Group is 7.7x.
What is the current FCF of Ebos Group?Ebos Group's last 12 months FCF is $93M.
What is Ebos Group's FCF margin?Ebos Group's last 12 months FCF margin is 1%.
What is the current EV/FCF multiple of Ebos Group?Current FCF multiple of Ebos Group is 39.0x.
How many companies Ebos Group has acquired to date?As of May 2026, Ebos Group has acquired 3 companies.
What was the largest acquisition by Ebos Group?$834M acquisition of LifeHealthcare on 9th December 2021 was the largest M&A Ebos Group has done to date.
What companies Ebos Group acquired?Ebos Group acquired LifeHealthcare, HPS Services, and Superior Pet Food Co..
In how many companies Ebos Group has invested to date?Ebos Group hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Ebos Group

Lists including Ebos Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial